PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31673238-4 2019 Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5muM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). Celecoxib 82-91 alkaline phosphatase, placental Homo sapiens 413-433 31673238-4 2019 Human osteoblasts obtained by primary culture from bone samples were treated with celecoxib at doses of 0.75, 2, or 5muM for 24 h. The MTT technique was used to determine the effect on proliferation; flow cytometry to establish the effect on cell cycle, cell viability, and antigenic profile; and real-time polymerase chain reaction to measure the effect on gene expressions of the differentiation markers RUNX2, alkaline phosphatase (ALP), osteocalcin (OSC), and osterix (OSX). Celecoxib 82-91 alkaline phosphatase, placental Homo sapiens 435-438 28007462-6 2017 Celecoxib inhibited the expression of both RUNX2 and ALP by suppressing their promoter activity. Celecoxib 0-9 alkaline phosphatase, placental Homo sapiens 53-56